Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 11;78(5):380–388. doi: 10.1093/jnen/nlz021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 American Association of Neuropathologists, Inc.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contactjournals.permissions@oup.com

PMC Copyright notice

FIGURE 3. — Immunohistochemistry of a large cohort of DIPGs indicated high expression of WT1 in H3.3 subtype compared with H3.1 subtype DIPGs. (A) IHC of a large cohort of DIPGs and pediatric midline gliomas showed WT1 overexpression in tumor compared with adjacent healthy brain tissue was valid. Scale bar = 50 µm. (B) Each tumor specimen was reviewed by a blinded neuropathologist and given an immunoreactivity score based on the number of WT1-positive cells. The pie chart shows the WT1 scores distribution of the specimens. (C) Examination of WT1 immunoreactivity scores revealed that WT1 scores of the specimens are associated with histone H3 mutation status. The distribution of WT1 immunoreactivity score was significantly different between H3.3 and H3.1 subtypes (Fisher exact test, p = 0.017). (D) qRT-PCR using cDNA from H3.3K27M DIPG tumor tissue (n = 3) and H3.1K27M DIPG tumor tissue (n = 2) showed higher expression of WT1 in H3.3K27M tumor specimens compared with H3.1K27M tumor specimens (6.4-fold).